Combined drug delivery methods and apparatus
First Claim
Patent Images
1. A therapeutic device to treat an eye, the device comprising:
- a non-permeable housing having a substantially fixed reservoir volume during implantation and use, wherein the reservoir volume is sized to extend through a sclera into a vitreous humor when the device is implanted in the eye;
a proximal cap portion coupled near a proximal end region of the housing and adapted to be positioned outside the sclera when the device is implanted in the eye, the cap portion comprising a retention structure and a penetrable, non-permeable barrier;
a narrow portion adjacent the proximal cap portion, the narrow portion having a cross-sectional shape defined along a plane perpendicular to a longitudinal axis of the device, wherein the cross-sectional shape of the narrow portion is defined at a widest location of the narrow portion by a first long width and a cross-sectional shape of the non-permeable housing is defined at a widest location of the non-permeable housing by a second long width such that the second long width of the non-permeable housing is greater than the first long width of the narrow portion;
a first chamber located within the reservoir volume and configured to hold a first therapeutic agent, the first chamber defining an opening at a distal end region of the first chamber, a first rigid, porous structure positioned within the opening at the distal end region of the first chamber, the first porous structure configured to be positioned in direct communication with the vitreous humor and comprised of sintered material; and
a second chamber located within the reservoir volume and configured to hold a second therapeutic agent, the second chamber defining an opening at a distal end region of the second chamber, a second rigid, porous structure positioned within the opening at the distal end region of the second chamber, the second porous structure configured to be positioned in direct communication with the vitreous humor and comprised of sintered material;
wherein the housing comprises a barrier extending through the reservoir volume from the proximal end region of the housing to a distal end region of the housing thereby forming the first chamber and the second chamber, and wherein at least one of the first and second chambers is refillable.
1 Assignment
0 Petitions
Accused Products
Abstract
Methods and apparatus provide treatment with a first therapeutic agent and a second therapeutic agent for an extended time. The first therapeutic agent may comprise a VEGF inhibitor and the second therapeutic agent may comprise an antiinflammatory, such as a non-steroidal anti-inflammatory, for example a cyclooxygenase inhibitor. One or more of the first therapeutic agent or the second therapeutic agent can be injected into the eye, for example injected into a therapeutic device implanted into the eye to release the injected therapeutic agent for an extended time.
-
Citations
20 Claims
-
1. A therapeutic device to treat an eye, the device comprising:
-
a non-permeable housing having a substantially fixed reservoir volume during implantation and use, wherein the reservoir volume is sized to extend through a sclera into a vitreous humor when the device is implanted in the eye; a proximal cap portion coupled near a proximal end region of the housing and adapted to be positioned outside the sclera when the device is implanted in the eye, the cap portion comprising a retention structure and a penetrable, non-permeable barrier; a narrow portion adjacent the proximal cap portion, the narrow portion having a cross-sectional shape defined along a plane perpendicular to a longitudinal axis of the device, wherein the cross-sectional shape of the narrow portion is defined at a widest location of the narrow portion by a first long width and a cross-sectional shape of the non-permeable housing is defined at a widest location of the non-permeable housing by a second long width such that the second long width of the non-permeable housing is greater than the first long width of the narrow portion; a first chamber located within the reservoir volume and configured to hold a first therapeutic agent, the first chamber defining an opening at a distal end region of the first chamber, a first rigid, porous structure positioned within the opening at the distal end region of the first chamber, the first porous structure configured to be positioned in direct communication with the vitreous humor and comprised of sintered material; and a second chamber located within the reservoir volume and configured to hold a second therapeutic agent, the second chamber defining an opening at a distal end region of the second chamber, a second rigid, porous structure positioned within the opening at the distal end region of the second chamber, the second porous structure configured to be positioned in direct communication with the vitreous humor and comprised of sintered material; wherein the housing comprises a barrier extending through the reservoir volume from the proximal end region of the housing to a distal end region of the housing thereby forming the first chamber and the second chamber, and wherein at least one of the first and second chambers is refillable. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16)
-
-
17. A therapeutic device to treat an eye, the device comprising:
-
a non-permeable housing having a substantially fixed reservoir volume during implantation and use, wherein the reservoir volume is sized to extend through a sclera into a vitreous humor when the device is implanted in the eye; a proximal cap portion coupled near the proximal end region of the housing and adapted to be positioned outside the sclera when the device is implanted in the eye; a narrow portion adjacent the proximal cap portion, the narrow portion having a cross-sectional shape defined along a plane perpendicular to a longitudinal axis of the device; a first chamber located within the reservoir volume and configured to hold a first therapeutic agent, the first chamber defining an opening at a distal end region of the first chamber, a first rigid, porous structure positioned within the opening at the distal end region of the first chamber, the first porous structure configured to be positioned in direct communication with the vitreous humor and comprised of sintered material; and a second chamber located within the reservoir volume and configured to hold a second therapeutic agent, the second chamber defining an opening at a distal end region of the second chamber, a second rigid, porous structure positioned within the opening at the distal end region of the second chamber, the second porous structure configured to be positioned in direct communication with the vitreous humor and comprised of sintered material; wherein the housing comprises a barrier extending through the reservoir volume from the proximal end region of the housing to a distal end region of the housing thereby forming the first chamber and the second chamber, and wherein at least one of the first and second chambers is refillable. - View Dependent Claims (18, 19, 20)
-
Specification